Business
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted
About this update from Passage Bio, Inc.
[{"type":"text","content":"On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory authorities for Imagine-1 study for GM1 gangliosidosis to treat patients at a third, higher dose; expect to dose first patient at Dose 3 in second half of 2023Continued momentum in upliFT-D trial for FTD with four global trial sites now initiatedExecution supported by strong balance sheet, with cash on hand to fund operations into first half of 2025 PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. “Over the last quarter, we have maintained a steady focus on the successful execution of our two lead clinical programs, taking the necessary steps to ensure the achievement of our upcoming milestones,” said William Chou, M.D., president and chief executive officer of Passage Bio. “In our Imagine-1 study for GM1 gangliosidosis, we expect to report safety and biomarker data for Cohort 4 by mid-year and begin dosing patients at a third, higher dose in the second half of this year. For FTD, we have expanded our recruitment sites to accelerate enrollment and look forward to reporting initial safety and biomarker data from Cohort 1 by year-end. Our disciplined approach and judicious cash management gives us confidence that we can deliver long-term value for patients and exemplifies our commitment to develop transformative therapies for people with devastating CNS disorders.” Recent Highlights Submitted protocol amendment for Imagine-1 study to treat patients at a higher dose (Dose 3) of PBGM01: The Imagine-1 clinical trial protocol amendment intends to treat early and late infantile GM1 gangliosidosis patients at a higher dose (Dose 3), which is two times higher than the current high dose (Dose 2). Following regulatory review, the company looks forward to resuming patient enrollment efforts and expects to the dose the first patient at Dose 3 in the second half of the year.Initiated additional site in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with ...